According to Ojing Medical's announcement, the company received the “Notice of Case Filing” issued by the China Securities Regulatory Commission on November 1, 2026, and the China Securities Regulatory Commission decided to file a case against the company due to suspected false records of financial data such as regular reports. If the facts later determined by administrative penalties touch upon a major illegal forced delisting situation, the company's shares will be subject to a major violation of the law and forced delisting. At present, the company's various operations, management, business and financial conditions are normal, and the company will actively cooperate with related work during the investigation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.